Healshape, a company developing a world-first breast prosthesis solution designed to regenerate patients’ own tissue following breast removal, has just closed a €6 million funding round. The round is led by GO CAPITAL (via the GO Capital Amorçage II fund) and DEMETER (via the FAIM fund), with participation from Bpifrance, via the French Tech Seed fund, Crédit Agricole Création, Win Equity, Angels Santé, a family office, the Institut de Cancérologie de l’Ouest (ICO) and private investors.
The medtech Healshape aims to offer an unprecedented breast bioprosthesis solution for women who have undergone a total or partial mastectomy. The prosthesis, 3D-printed from natural materials, is able to enable the regeneration of the patient’s tissue and to be resorbed in the months following surgery, leaving only the original tissue in place. Thanks to this transitional, natural implant, the patient regains her own breast within a few months. This minimally invasive solution, compatible with current surgical practices, allows the placement of a prosthesis made of 100% bio-based materials, representing a genuine alternative to existing solutions, which most often require complex surgery or synthetic materials.